Conferences
European Pharmacopoeia prepares for the future through exchange with stakeholders
To mark the publication of the 9th edition of the European Pharmacopoeia (Ph. Eur.), the EDQM (European Directorate for the Quality of Medicines) organized a large international conference in Tallinn, Estonia, which brought together representatives of European and international regulatory authorities, the World Health Organization (WHO), pharmacopoeias from different continents as well as industry and associations from Europe and beyond. Participants came from 41 different countries, including Brazil, Canada, India, Japan, South Africa, Taiwan and USA.
Extrapolation key issue at European biosimilars conference
The European Generic medicines Association (EGA) held its 13th EGA-European Biosimilars Group Conference in London on 23–24 April 2015.
French generics association promotes biosimilars
French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.
Topics presented at the 16th IGPA conference on generics
Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.
EGA pushes for increased focus on generics and biosimilars
EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.
Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands
Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, addressed by 300+ Speakers from EMA, European Commission, FDA and other national regulatory agencies. Most popular sessions included Implementation of the New Pharmacovigilance Legislation, the Regulatory Town Hall Meeting and the sell-out European Landscape on HTA - the EUnetHTA Joint Action. Eighteen pre-conference tutorials were led by an expert faculty and 120 students, young professional and patients all attended sessions created especially for them.
Patient power predominates at DIA Europe’s Clinical Forum
DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The theme for 2012 is ‘The Empowered Patient’, an acknowledgement of the inescapable fact that the evolution of technology and electronic communication has given patients the ability to find and share health information which will impact their treatment choices – empowering them to become more engaged in their care and to participate in decisions about it.
Need for global development programme for biosimilars
There is now a crucial need for a framework that allows global biosimilars development.
Removal of barriers for the global development of biosimilars
At the 2012 Biosimilars Medicines: 10th EGA International Symposium, held in London, UK, on 19–20 April 2012; Mr Nils Behrndt (Deputy Head of Cabinet DG Sanco, European Commission) announced that the European Commission (EC) wishes to stimulate the global development of biosimilars. The EC has thereby two objectives:
European Commission calls for wider use of generic medicines
At the 10th International Symposium on Biosimilar Medicines, organised by the European Generics medicines Association, held in London, UK, on 19–20 April 2012; the European Commission (EC) highlighted the need to stimulate wider use of generic medicines.
